Clinical Trial Update: ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML [Phase 1]

View source ↗

Summary

This is a Phase 1 clinical trial assessing a quadruple combination of ABL001 (asciminib), dasatinib, prednisone, and blinatumomab in patients with BCR-ABL1-posi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia in Lymphoid Blast Crisis
• Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

Drugs mentioned

• Asciminib (ABL001) (asciminib)
• BLINCYTO (BLINATUMOMAB)
• Deltasone (prednisone)
• Sprycel (dasatinib)

Snippet

Sponsor: Marlise Luskin, MD | Conditions: B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis | Phase 1 | Status: RECRUITING